Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields plus temozolomide for newly diagnosed glioblastoma
ChiCTR2400079889Phase 3Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2400079889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079889.